Virology and Immunology: The Basics. Dr Tristan Barber
|
|
- Kelly Burns
- 5 years ago
- Views:
Transcription
1 Virology and Immunology: The Basics Dr Tristan Barber
2 Objec9ves HIV life cycle Stages of HIV Infec7on Virology Immunology Basics of resistance
3 Life Cycle
4
5 Stages of Infec9on
6
7 Stages of HIV infec9on Primary HIV infec7on Asymptoma7c HIV infec7on Symptoma7c HIV infec7on AIDS diagnosis
8 Primary HIV Infec9on Inflammatory response HIV- specific CD4 cells are infected An7body tests are nega7ve An7gen posi7ve HIV viral load elevated
9 Primary HIV Infec9on Inflammatory response HIV an7bodies (within 6 wks but <3 mths) Window period High levels of HIV in blood, sexual fluids and/ or breast milk Highly infec7ous!
10 Asymptoma9c HIV infec9on This stage lasts for an average of ten years Free from major symptoms Viral load drops from seroconversion but remains infec7ous HIV an7body posi7ve Not dormant, very ac7ve in the lymph nodes
11 Symptoma9c HIV infec9on Over 7me immune system becomes severely damaged The lymph nodes and 7ssues become damaged HIV mutates and becomes more pathogenic CD4 cells become depleted Symptoms start mild and increase in severity Emergence of opportunis7c infec7ons
12 Immunology
13 Basics CD4 cells What do they do? What s normal? Numbers or percentage? CD8 cells Any other tests? HLA B5701
14 Opportunis9c infec9ons CD4 > 500 cells/mm 3 - usually not at risk CD cells/mm 3 - Candidiasis (Thrush) - Kaposi s Sarcoma (KS) - Tuberculosis (TB) - Lung infec7ons
15 Opportunis9c infec9ons cells/mm 3 - Toxoplasmosis - Cryptosporidiosis - Cryptococcal Infec7on - Cytomegalovirus (CMV) <50 cells/mm 3 - Mycobaterium Avium complex (MAC)
16 Virology
17 Virology An7bodies and an7gens Hepa77s from A. To Z? HIV viral load What does it mean? How quickly should it go away? What s a log drop?
18 Resistance (is useless)
19 Resistance What is resistance? Why does it mager? What strategies do we use to reduce development of resistance?
20 HIV - replica9on and muta9on Approx 5000 new virions per ml of blood per day (30 million+ virions) No checking mechanism Rapid muta7on rate Viral escape mutants A replica9ng virus is a muta9ng virus lead to theory of HAART
21 What is a muta9on? HIV enzymes (reverse transcriptase, protease ) are made up of proteins The subunits of proteins are amino acids Each amino acid is coded for by a triad of nucleosides A, C, T, G Hence AZT, 3TC, d4t etc 1 muta7on = change in 1 nucleoside that may or may not change the amino acid A muta7on is a change in the gene7c code of an organism, which may change the way in which the organism looks and behaves
22 Discussion Why does treatment failure occur? Why does resistance occur?
23 Why do resistance and treatment failure occur? Commonly for 4 reasons: A random occurrence Drug interac7on decreasing effec7veness Malabsorp7on Nonadherence to the treatment regimen Pa7ent choice Side effects Life events
24 HIV drugs and resistance Some drugs have a low gene7c barrier to resistance One point muta7on may confer resistance to a par7cular drug or en7re drug class e.g. some nucleoside drugs (NRTIs) or non- nucleosides (NNRTIs) Some drugs have high gene7c barrier Step wise accumula7on of resistance muta7ons need to develop resistance e.g. boosted protease inhibitors (PIs)
25 Barriers to resistance Single PI Small change per mutation BUT Low drug levels NNRTIs High drug levels BUT Large change per mutation Boosted PIs Small change per mutation AND High drug levels High trough High trough Low trough EC 50 EC 50 Increasing EC 50 Increasing number of mutations
26 Minimizing resistance Use combina7on therapy (HAART) Use boosted PIs Maximise adherence (>95%) Tolerable Simple Alarms/other adherence support Use drugs with long/matched half lives Don t interrupt therapy
27 Types of failure Clinical Immunological Virological
28 Types of resistance Clinical resistance HIV mul7plies in your body even though you are taking an7viral drugs Genotypic resistance The gene7c code of HIV has muta7ons that are linked to drug resistance Phenotypic resistance HIV mul7plies in a test tube when an7viral drugs are added
29 Genotypic tes9ng Gene7c code of sample virus compared to wild type Each codon defines an amino acid used to build a new virus Currently sequence genes coding for reverse transcriptase (RT) and protease enzymes Legers and numbers are used to describe muta7ons
30 3TC Resistance ATG to ATA ATG = methionine ATA = valine Hence M184V Old amino acid New amino acid Position of mutation ie. 184 th amino acid Along chain
31 Phenotypic tes9ng Sample of HIV grown in the laboratory Dose of an an7retroviral drug is added Growth rate of HIV is then compared to wild type virus If sample grows more than normal it is resistant to the drug Results reported as fold resistance This is a direct measure of in vitro resistance
32 Virtual phenotype Perform genotype Compare results to phenotypes of viruses with similar pagern Less expensive Faster Dependent on database
33 Ques9ons
34 BREAK
35 Working. Together. Dr Tristan Barber
36 Personal Experiences
37 Being an HIV doctor Holis7c Global Pa7ent focussed Progressive Evolving Challenging Liberal Boundaries C.A.M.P. (yes, really) Teaching The bigger picture sharing our model
38 Working in the NHS Pride Cost effec7ve Opportuni7es Collabora7on Centres of excellence Joined up care Virtual consulta7ons Holis7c Preven7on Threats Commissioning Uncoupling from sexual health Losing local services to bigger centres Staff pressures
39 Working Together
40 An holis9c approach... If a pa-ent only sees a clinician, they only get half the story Dr Simon Edwards Mor7mer Market Centre
41 Working together User interac7on is essen7al in HIV services How can doctors and advocates work together?
42 What is it? Can be local/na7onal/interna7onal Not always NGO/voluntary sector; can be clinic/pa7ent based Individual/group Different role in urban vs. rural sewngs Pa7ent focussed May involve aspects of role modelling living posi7vely, managing meds/side effects Management/poli7cal level Mee7ngs, campaigning, advoca7ng Voluntary or paid
43 What s gained? Understanding of needs pa7ent/community Biological, psychological, social Ability to beger public health and preven7on strategies Encouraging adherence/agendance Personal empowerment Leverage with funding threats Extra weight to commissioning of services S7gma reduc7on Experiences shared Diagnosis Disclosure Rejec7on S7gma and discrimina7on
44 Mulitple possibili9es Direct client involvement and support Wri7ng pa7ent informa7on/leaflets Telephone advice Maintaining websites Quality control Campaigning locally, na7onally, interna7onally Human rights New drugs (mul7) media
45 Self s9gma Self- s7gma amongst people at risk for, and living with HIV, results in self- discriminatory decisions or ac7ons that can include: self- isola7on from family, friends and support depression self- harming prac7ces and risk taking missed HIV tes7ng opportuni7es, clinic appointments, necessary treatments hospitalisa7ons suicidal idea7on and ac7ons
46 Pa9ent Reps: Bloomsbury Clinic Employed pa7ent reps Peer support, advice, advocacy and means of engagement One on one appointments as well as coordina7ng the pa7ent network Workshops, forums, courses and social events Administering emergency financial funds Represent pa7ents on external commigees, advisory panels, working par7es and on the boards of chari7es
47 Varied roles Social isola7on and exclusion Disclosure and confiden7ality issues Social and psychological issues Diagnosis and life expectancy Star7ng treatment and adherence Physical health and well- being Dental care and GPs Pregnancy, paren7ng, adop7on and fostering Onward referrals for legal advice, immigra7on, employment, benefits, housing and homelessness Onward referrals to our own health advisors and psychology department or external counselling
48 Peer HUH Informed by mentor mothers (PUK) and mothers2mothers programme Peer Navigator posts recruited from local cohort; MAC AIDS grant Based on early ini7a7ve in Global South Can it work it London, can it be genericised? To ensure needs are met, PLWHIV have to be able to effec7vely navigate various health and social care networks/systems In this cohort, there are mul7ple barriers that restrict effec7ve access to care, including some men7oned but also en7tlement to treatment Therefore people in most need struggle to navigate effec7vely, which can impact on their overall health outcomes Peer Navigators enable people to navigate the various systems effec7vely and appropriately
49 Conclusions Rolediversely implemented in different areas (and clinics) User involvement helps at individual level as well as at service provision/poli7cal level Strengthening of pa7ent centred care Peer support helps come to terms with diagnosis Empowerment through informa7on Skills and coping mechanisms Development of inner strengths and resources User involvement key at pa7ent level as well as at na7onal/ interna7onal poli7cal level Supplement and enhance pa7ent care
50 Ques9ons
2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationSummary of ARV prescribing guidelines in London
Summary of ARV prescribing guidelines in London These slides summarise the recommenda1ons by the London HIV Consor1um for prescribing an1retrovirals. April 2011 HIV posi1ve people should discuss these
More informationUsing Implementation Science to Address Prevention of Mother to Child Transmission of HIV
Using Implementation Science to Address Prevention of Mother to Child Transmission of HIV Dr. Laura Guay Vice President for Research Elizabeth Glaser Pediatric AIDS Founda@on 1 The role of Implementation
More informationGenetic Tests and Genetic Counseling How to Analyze Your Own Genome
Genetic Tests and Genetic Counseling 02-223 How to Analyze Your Own Genome Genetic Tests for Huntington Disease Hun7ngton Disease Incurable brain disorder that runs in families Movement, cogni7ve, and
More informationOncology Care Model Overview
Oncology Care Model Overview Centers for Medicare & Medicaid Services Innova3on Center (CMMI) September 2017 Innova3on at CMS Center for Medicare & Medicaid Innova3on (Innova3on Center) Established by
More informationReproductive Health Decision- Making among Women Living with HIV. Lisa J. Messersmith, PhD, MPH Boston University School of Public Health
Reproductive Health Decision- Making among Women Living with HIV Lisa J. Messersmith, PhD, MPH Boston University School of Public Health RH decision- making along a continuum Ê Desire for children Ê Sexual
More informationSECTION 1: ABOUT HEPATITIS
SECTION 1: ABOUT HEPATITIS Hepa33s Means Swollen Liver Many things can cause your liver to become swollen, including drinking a lot of alcohol; taking certain medica3ons or herbs; inhaling toxic fumes;
More informationPatients at High Risk Experience, Guidelines, and Best Practices. Mozambique. José Tique, MD MPH MoH July 17-19, 2017 Harare, Zimbabwe
Patients at High Risk Experience, Guidelines, and Best Practices Mozambique José Tique, MD MPH MoH July 17-19, 2017 Harare, Zimbabwe Content Scope of the Problem Treatment Guidelines Best Prac9ces Differen9a9ng
More informationWHO posi)on paper on hepa))s A vaccines
WHO posi)on paper on hepa))s A vaccines Geneva, Switzerland Published in the Weekly Epidemiological Record on 13 July 2012 Transmission and incidence Hepa))s A virus (HAV) is transmiled primarily via the
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationTuberculosis: What's new in diagnos6cs and management?
Tuberculosis: What's new in diagnos6cs and management? Colin Menezes, Department of Internal Medicine, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand. Objec6ves of this talk:
More informationOffice of Training and Capacity Development AIDS Educa<on and Training Centers Overview
Office of Training and Capacity Development AIDS Educa
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationMental Health Strategy. Easy Read
Mental Health Strategy Easy Read Mental Health Strategy Easy Read The Scottish Government, Edinburgh 2012 Crown copyright 2012 You may re-use this information (excluding logos and images) free of charge
More informationThe Genetic Barrier to Resistance
The Genetic Barrier to Resistance Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Beijing, May 2013 The Genetic Barrier to Resistance The genetic
More informationPrevention and wellbeing. Amanda McGlennon Richmond CCG Debbie Davies East London NHS Foundation Trust Val Farmer Richmond Borough Mind
Prevention and wellbeing Amanda McGlennon Richmond CCG Debbie Davies East London NHS Foundation Trust Val Farmer Richmond Borough Mind Prevention and wellbeing All services should be delivered to support
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationMeaningful Use of Meaningful Use
Meaningful Use of Meaningful Use Kevin Larsen MD Medical Director, Meaningful Use Office of the Na;onal Coordinator of Health IT March 7 2013 Our Na;onal Quality Strategy Aims Be#er Health for the Popula0on
More informationFor personal use only
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 22 November 2016 The Manager Companies ASX Limited
More informationSuppor&ng the Mental Health of Looked- A7er Children Across the Primary- Secondary Transi&on
Suppor&ng the Mental Health of Looked- A7er Children Across the Primary- Secondary Transi&on Helen Drew, & Robin Banerjee (University of Sussex), Mary John (University of Surrey) and Nikki Luke & Judy
More informationGlobal Treatment Access Review Par$cipatory Methodology. Dr. Alice Welbourn Salamander Trust Founding Director
Global Treatment Access Review Par$cipatory Methodology Dr. Alice Welbourn Salamander Trust Founding Director Presenta5on overview What research exists? Research ques$ons Theore$cal Framework Key review
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More information1. ATHENA Network, AVAC, and Salamander Trust with UN Women, undertook this mul>-stage review of the global status of access to an>retroviral therapy
1. ATHENA Network, AVAC, and Salamander Trust with UN Women, undertook this mul>-stage review of the global status of access to an>retroviral therapy (ART) for women living with HIV 2. This is the first
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationClinical Management Guidelines 2012
Central American Course Monitoring and Evaluation for HIV/AIDS Policy and Program Management 1 2 3 4 Module 1 Unit 1 Clinical Management Guidelines 2012 National TB, HIV/AIDS & other STIs Programme Ministry
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationSECTION 1: ABOUT HEPATITIS
SECTION 1: ABOUT HEPATITIS Hepa33s means swollen liver Many things can cause your liver to become swollen, including drinking a lot of alcohol; taking certain medica3ons or herbs; inhaling toxic fumes;
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationMaternal Mortality and HIV: Examining Research through a Programma;c Lens. Day 1 Recap
Maternal Mortality and HIV: Examining Research through a Programma;c Lens Day 1 Recap Introduc;on Every day, approximately 800 women die from preventable causes related to pregnancy and childbirth. 99%
More informationUpdates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013
Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will
More informationMortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013
John F. White III, MD, MBA, FLMI VP and Medical Director American National Insurance Company 1 Mortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013 2 1 3 My Opinions
More informationNutrigenetics and Nutrigenomics in Clinical Research and Practice
Nutrigenetics and Nutrigenomics in Clinical Research and Practice Mar$n Kohlmeier, MD, PhD University of North Carolina at Chapel Hill Department of Nutri7on and UNC Nutri7on Research Ins7tute mkohlmeier@unc.edu
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More informationReaching Men with Community Outreach. Peris Urasa National AIDS Control Programme, Tanzania 6 November 2018
Reaching Men with Community Outreach Peris Urasa National AIDS Control Programme, Tanzania 6 November 2018 Ministry of Health, Community Development, Gender, Elderly and Children Na;onal AIDS Control
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationEffec&ve Messaging for Suicide Preven&on:
Effec&ve Messaging for Suicide Preven&on: Anara Guard anara@suicideispreventable.org Lessons from a statewide campaign and from a na&onal framework This morning The Know the Signs statewide social marke&ng
More informationI know it because I live it An In-clinic peer mentorship scheme to improve outcomes in adolescents living with HIV
I know it because I live it An In-clinic peer mentorship scheme to improve outcomes in adolescents living with HIV Theme: Working with Patients and Communities Alison Barnes, MSN MPH HIV in the UK Over
More informationCh 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems
Ch 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems Highlight Disease: Malaria World s dominant protozoal disease. Four species of Plasmodium: P. falciparum (malignant), P. vivax (begnin),
More informationCases from the Perinatal HIV Hotline
Cases from the Perinatal HIV Hotline Contracep*on, Preconcep*on, and Concep*on Chris*ne Pecci & Lealah Pollock Clinician Consulta*on Center, UCSF Objec*ves To encourage all clinicians to ask all pa*ents
More informationVoluntary Medical Male Circumcision in Military Populations: September 2012 Update
Voluntary Medical Male Circumcision in Military Populations: September 2012 Update Anne Goldzier Thomas, Ph.D. US Department of Defense PEPFAR Male Circumcision TWG Johannesburg, South Africa Combina(on
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationScottish Medicines Consortium
Scottish Medicines Consortium darunavir 300mg tablets (Prezista ) No. (378/07) Tibotec (a division of Janssen-Cilag Ltd) 4 May 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationWe ve Come a Long Way Baby! Forget the cigare7es, I want a vaginal swab!
We ve Come a Long Way Baby! Forget the cigare7es, I want a vaginal swab! Who I am Director, Infec@ous Diseases Laboratory at University of Alabama at Birmingham School of Medicine I captured Chlamydia
More informationversus CD4. PoC - Messaging - Specificity and - Ethics sensitivity of HIV - Feedback from diagnostic tests demonstration projects
PRE-CONFERENCE WORKSHOPS WEDNESDAY, 24 OCTOBER 2018 10h00 14h00 Pre-Conference Workshop Pre-Conference Workshop Pre-Conference Workshop Pre-Conference Workshop ITREMA trial feedback PrEP for the private
More informationGuidelines For Services Providing Injecting Equipment
Guidelines For Services Providing Injecting Equipment Best Practice Recommendations For Commissioners and Injecting Equipment Provision (IEP) Services in Scotland (Scottish Government 2010) January 2014
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationPRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES
PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES Mark A. Wainberg McGill University AIDS Centre Jewish General Hospital Montreal, Quebec,
More informationHepatitis C Strategy. About us. What is hepatitis C?
Hepatitis C Strategy About us We support people to take control of their lives and make positive changes. For fifty years we have made a difference to people who want to change their relationship with
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More information10/17/2015. Chapter 55. Care of the Patient with HIV/AIDS. History of HIV. HIV Modes of Transmission
Chapter 55 Care of the Patient with HIV/AIDS All items and derived items 2015, 2011, 2006 by Mosby, Inc., an imprint of Elsevier Inc. All rights reserved. History of HIV Remains somewhat obscure The earlier
More informationPresented by: Melissa Egan, Regional Health Education Coordinator, CATIE Date: Tuesday October 8th, 2013, 1 2pm EST
Presented by: Melissa Egan, Regional Health Education Coordinator, CATIE Date: Tuesday October 8th, 2013, 1 2pm EST Agenda 1. HIV and the immune system 2. The progression of untreated HIV 3. Monitoring
More informationWHO posi)on paper on pneumococcal vaccines. Geneva, Switzerland Published in the Weekly Epidemiological Record on 6 Apr 2012
WHO posi)on paper on pneumococcal vaccines Geneva, Switzerland Published in the Weekly Epidemiological Record on 6 Apr 2012 WHO posi)on paper on pneumococcal vaccines, April 2012 The current posi)on paper
More informationFindings from the At Home / Chez Soi Demonstration Project in Canada. Paula Goering and Catharine Hume May 2, 2013
Findings from the At Home / Chez Soi Demonstration Project in Canada Paula Goering and Catharine Hume May 2, 2013 Outline for today Overview of Project Design Na8onal level findings re one year outcomes
More informationHIV DRUG RESISTANCE AND STEWARDSHIP 3 RD LINE PROGRAMME
HIV DRUG RESISTANCE AND STEWARDSHIP 3 RD LINE PROGRAMME SOUTHERN AFRICAN HIV CLINICIANS SOCIETY CONFERENCE - 2014 26 SEPTEMBER 2014 Khadija Jamaloodien Affordable Medicines ANTIMICROBIAL STEWARDSHIP The
More informationHIV in the UK: Changes and Challenges; Actions and Answers The People Living With HIV Stigma Survey UK 2015 Scotland STIGMA SURVEY UK 2015
HIV in the UK: Changes and Challenges; Actions and Answers The People Living With HIV Stigma Survey UK 2015 Scotland STIGMA SURVEY UK 2015 SCOTLAND The landscape for people living with HIV in the United
More informationCollabora'on to Prevent and Control Cervical Cancer in La'n America and the Caribbean
Collabora'on to Prevent and Control Cervical Cancer in La'n America and the Caribbean Partnership between PAHO- USG- ACS- RINC Mona Saraiya, MD, MPH CDC Associate Director for Interna@onal Cancer Control
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationHIV Program and Data Integration. Bruce Taylor Anne Rhodes, PhD Division of Disease Prevention Virginia Department of Health
HIV Program and Data Integration Bruce Taylor Anne Rhodes, PhD Division of Disease Prevention Virginia Department of Health Division of Disease Prevention: Virginia HIV Surveillance HIV Care Services STD
More informationIntroduc)on to An)retroviral Drug Resistance
Introduc)on to An)retroviral Drug Resistance Harry Lampiris, MD Professor of Clinical Medicine, UCSF Ac;ng Chief, Infec;ous Disease Sec;on San Francisco VA Medical Center December 7, 2012 HIV Drug Resistance
More informationIMPAACT TB SCIENTIFIC COMMITTEE. Anneke C Hesseling: Chair Sharon Nachman: Interim Vice Chair IMPAACT Vice Chair
IMPAACT TB SCIENTIFIC COMMITTEE Anneke C Hesseling: Chair Sharon Nachman: Interim Vice Chair IMPAACT Vice Chair Goal Address cri>cal therapeu>c research gaps in the preven>on and treatment of tuberculosis
More informationDisclosure Informa0on Western Occupa0onal Health Conference 2012
Infec&ous Disease: Guidelines, Updates & Implementa&on in the Health Care Se=ng James Watt, MD, MPH Chief, Division of Communicable Disease Control Center for Infectious Diseases California Department
More informationUptake of Treatment as Preven1on for HIV and Con1nuum of Care Among HIV- posi1ve Men Who Have Sex With Men in Nigeria
Uptake of Treatment as Preven1on for HIV and Con1nuum of Care Among HIV- posi1ve Men Who Have Sex With Men in Nigeria Man Charurat Associate Professor of Medicine and Epidemiology Ins:tute of Human Virology
More informationHCV TREATMENT OPTIONS
HCV TREATMENT OPTIONS Trea2ng HCV is never an emergency, but early treatment prevents further liver damage. DAAs are easier to take, and be0er tolerated than PEG- IFN and RBV. Treatment is recommended
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationWhat Does HIV Do to You?
What Does HIV Do to You? HIV and the immune system Your immune system is supposed to protect you from viruses and other infections. Why, then, doesn t it protect you from HIV? The answer is complicated,
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More information1592U89 (Abacavir) Resistance and Phenotypic Resistance Testing
1592U89 (Abacavir) Resistance and Phenotypic Resistance Testing Reported by Jules Levin, Executive Director of NATAP (3 March 1998) The following report contains a comprehensive update of the latest information
More informationMolecular mechanisms in atopic eczema - why do they ma6er in the clinic?
Molecular mechanisms in atopic eczema - why do they ma6er in the clinic? Sara Brown Professor of Molecular & Gene0c Dermatology Wellcome Trust Senior Fellow in Clinical Research Professor of Molecular
More informationEvolving Realities of HIV Treatment in Resource-limited Settings
Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has
More informationCLAUDINE HENNESSEY & THEUNIS HURTER
HIV/AIDS/TB CLAUDINE HENNESSEY & THEUNIS HURTER KEY TERMS Do these sound familiar? What strange terms do you hear in the clinics? Any others to add?? HIV AIDS Viral Load & suppression CD4 count Regimen
More informationInvestor Newsletter. 1,386 HOUSEHOLD MEMBERS LGBT households that are members of New Family Social. They may be single or couples.
PAGE ONE JUNE 2016 Investor Newsletter Strong and happy LGBT About adoptive New Family & foster Social families throughout the UK New Family Social is the only na2onal charity that provides personal and
More informationDiagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know
Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know Carolyn K. Burr, EdD, RN Co-Clinical Director Deputy Director François-Xavier Bagnoud Center December 17 th, 2013
More informationBIOTRON LIMITED (ASX:BIT) Biotech Showcase 2017
BIOTRON LIMITED (ASX:BIT) Biotech Showcase 2017 Forward Looking Statements This presenta,on may contain forward-looking statements with respect to the financial condi,on, results and business achievements/performance
More informationMETRO ASSOCIATES WELCOME PACK
METRO ASSOCIATES WELCOME PACK METRO N106 Westminster Business Square 1-45 Durham Street SE11 5JH Charity No. 10707582 Contents Welcome!... 3 Introduction... 3 Statement from Scott... 4 How the scheme works...
More informationThailand Na*onal CAB AVAC Partners Forum 25 th March 2015
Thailand Na*onal CAB 2015 AVAC Partners Forum 25 th March 2015 Background The first CAB in Thailand was found over 10 years ago in prepara*on of a phase 3 HIV vaccine trial 10 HIV CABs in the country:
More informationHIV and drug resistance Simon Collins UK-CAB 1 May 2009
HIV and drug resistance Simon Collins UK-CAB 1 May 2009 slides: thanks to Prof Clive Loveday, Intl. Clinical Virology Centre www.icvc.org.uk Tip of the iceberg = HIV result, CD4, VL Introduction: resistance
More informationHemophilia Federa.on of America Inhibitor Track 3/26/2015. Developed by Debbie Porter, Reduce Inhibitor Development (RID) 1
MISSION The Hemophilia Federation of America (HFA) is a national nonprofit organization that assists and advocates for the bleeding disorders community. RID Reduce Inhibitor Development Debbie Porter March
More informationRACP Clinical Exam Prepara5on - Immunology Tutorial
General Approach to the Long Case RACP Clinical Exam Prepara5on - Immunology Tutorial Dr Winnie Tong Advanced Trainee Liverpool Hospital July 2009 Spend 5 minutes establishing rapport Have you helped out
More informationHIV Update For the Internist
HIV Update For the Internist Disclosures I declare that I have received no incentives, financial or otherwise, from pharmaceutical or biomedical companies relevant to the content of this talk. As an Infectious
More informationSession 1 Basic HIV Facts. Patient Navigation Intervention
Session 1 Basic HIV Facts Patient Navigation Intervention Session 1 HIV, the Viral Life Cycle & Understanding the Importance of HAART and Adherence https://www.aids.gov/hiv aids basics/just diagnosed with
More information2018 Conference on Ending Homelessness. Informa(onal Session Proposal Webinar
2018 Conference on Ending Homelessness Informa(onal Session Proposal Webinar Welcome To The Webinar Thank you for joining today s webinar! All par:cipants will be muted during the webinar to ensure good
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationMental Health Voluntary Sector Support Services in Milton Keynes. Presentation to the Adult Social Care and Health Select Committee 7 th October 2014
Mental Health Voluntary Sector Support Services in Milton Keynes Presentation to the Adult Social Care and Health Select Committee 7 th October 2014 Voluntary Sector Support Services Welcome & Introductions
More informationSession 1B - Auditorium Adult cases - Adherence - Mental health - STIs - Opportunistic Infections - TB - Drug Interactions Panel discussion
CONFERENCE PROGRAMME WEDNESDAY, 24 OCTOBER 2018 08h00 18h00 Registration OFFICIAL MEETING COMMENCES 14h00 15h30 Session 1A Adolescent cases - Teen pregnancy and breast feeding - Previously on PrEP, now
More informationHuman Immunodeficiency Virus. Acquired Immune Deficiency Syndrome AIDS
Human Immunodeficiency Virus Acquired Immune Deficiency Syndrome AIDS Sudden outbreak in USA of opportunistic infections and cancers in young men in 1981 Pneumocystis carinii pneumonia (PCP), Kaposi s
More informationIntroduction to Microbes and Infectious Disease
Name: Date: Introduction to Microbes and Infectious Disease Station 1) Pathogens Pathogens are capable of causing. Examples: Station 3) Discovery My name is Anton von Leeuwenhoek, and in I documented my
More informationRecovery as an issue of social justice and social inclusion
Recovery as an issue of social justice and social inclusion Professor David Best Sheffield Hallam University / Monash University November 2016: Copenhagen The central values of the centre: widening access
More informationIncreasing the benefits of foster carer peer support
Increasing the benefits of foster carer peer support Nikki Luke and Judy Sebba Rees Centre for Research in Fostering and Educa;on rees.centre@educa;on.ox.ac.uk Rees Centre for Research in Fostering and
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationInsights from CISCRP s 2017 Percep9ons & Insights Study March 2018
Insights from CISCRP s 2017 Percep9ons & Insights Study March 2018 Summary Overall public and patient attitudes, perceptions and experiences consistent with past studies Probing to identify underlying
More informationCase Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.
Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous
More informationEthics and Boundaries
Ethics and Boundaries Jim Seckman, MAC, CACII, CCS What are the defining characteris@cs of a profession? A body of knowledge A special group of skills Addresses a special problem Tes@ng for admission Lifelong
More informationEconomic outcomes: Method for implementa5on
Economic outcomes: Method for implementa5on Philippe Beutels Centre for Health Economics Research & Modelling Infec
More informationHerpes virus co-factors in HIV infection
Herpes virus co-factors in HIV infection Dr Jane Deayton Barts and the London Queen Mary School of Medicine Introduction Herpes viruses very common and often coexist with HIV Establish life-long latent
More information2009 Revisions of WHO ART Guidelines. November 2009
2009 Revisions of WHO ART Guidelines November 2009 Guidelines Development Process 01/09 2009 WHO ART guideline revision process Scope of the work 03/09 WHO Guideline review committee approval 04/09 05/09
More informationPathology Course Immunology 1 Ann Sturdy
Pathology Course Immunology 1 Ann Sturdy Kindly sponsored by: Plan Transplant Immune- Based Therapies Vaccina:on and Memory HIV Transplant (Page 102) Immunology of Transplant Transplant rejec5on is the
More informationPhysiology Unit 3 THE SPECIFIC IMMUNE RESPONSE
Physiology Unit 3 THE SPECIFIC IMMUNE RESPONSE The Adap4ve Arm of the Immune System Specific Immune Response Internal defense against a specific pathogen Acquired as you are exposed to diseases The immune
More information